Evidence map›Paper›PMID 38539172›Full record

ArticleBMC pulmonary medicine2024

Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak.

Pan-Pan Xie, Yue Zhang, Wen-Kai Niu, Bo Tu, Ning Yang, Yun Fang, Ying-Hui Shi, Fu-Sheng Wang, Xin Yuan

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pan-Pan Xie *Anhui Medical University PLA 307 Clinical College, Beijing, China.
Yue Zhang *Department of Respiratory and Critical Care Diseases, Senior Department of Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Wen-Kai Niu *Department of Respiratory and Critical Care Diseases, Senior Department of Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Bo TuDepartment of Respiratory and Critical Care Diseases, Senior Department of Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Ning YangDepartment of Respiratory and Critical Care Diseases, Senior Department of Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Yun FangDepartment of Respiratory and Critical Care Diseases, Senior Department of Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Ying-Hui ShiDepartment of Respiratory and Critical Care Diseases, Senior Department of Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Fu-Sheng WangSenior Department of Infectious Diseases, the Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. fswang302@163.com.
Xin YuanAnhui Medical University PLA 307 Clinical College, Beijing, China. xinyuannatile@sina.com.
Chinese PLA General Hospital · CN

Funding

National Key Research and Development Program of China 2020YFC0860900the Top-Notch Project for Youth Training 20QNPY115
6 · The paper itself

Abstract

backgroundChronic cough is a common symptom in patients post the coronavirus disease 2019 (COVID-19). In this study, we aimed to investigate the efficacy of inhaled corticosteroids (ICS) and the clinical characteristics of patients with post-COVID-19 chronic cough during the Omicron era.

methodsAn ambispective, longitudinal cohort study was conducted that included patients with post-COVID-19 who attended the respiratory clinic at our hospital between January 1, 2023, and March 31, 2023 with a complaint of persistent cough lasting more than 8 weeks. At 30 and 60 days after the first clinic visit for post-COVID-19 chronic cough, enrolled patients were prospectively followed up. We compared the changes in symptoms and pulmonary function between patients receiving ICS treatment (ICS group) and those not receiving ICS treatment (NICS group) at the two visits.

resultsA total of 104 patients with post-COVID-19 chronic cough were enrolled in this study (ICS group, n = 51; NICS group, n = 53). The most common symptoms accompanying post-COVID-19 chronic cough were sputum (58.7%, 61/104) and dyspnea (48.1%, 50/104). Seventy-one (82.6%, 71/86) patients had airway hyperresponsiveness, and 49 patients (47.1%, 49/104) were newly diagnosed with asthma. Most patients (95.2%, 99/104) exhibited improvement at 60 days after the first visit. The pulmonary function parameters of the patients in the ICS group were significantly improved compared to the baseline values (P < 0.05), and the improvement in the FEV

conclusionsSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may contribute to the pathogenesis of asthma, which could be the underlying cause of persistent cough post-COVID-19 infection. Post-COVID-19 chronic cough during the Omicron era was often accompanied by sputum, dyspnea, and airway hyperresponsiveness. ICS treatment did not have a significant impact on symptom management of post-COVID-19 chronic cough; however, it can improve impaired lung function in in these individuals.

Indexed as

AsthmaCOVID-19Administration, InhalationAdrenal Cortex HormonesChronic CoughCoughDyspneaHumansLongitudinal StudiesSARS-CoV-2Adrenal Cortex HormonesChronic coughInhaled corticosteroid (ICS)Long COVIDOmicronpost-COVID-19 syndromeViral infection related-asthma

Identifiers

PMID38539172
PMCPMC10967081
OpenAlexW4393233262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.